Standard PA criteria across payers typically include: Confirmed diagnosis of primary hyperlipidemia or HeFH or HoFH with supporting ICD-10 code Documented LDL-C level above payer-specified threshold (commonly 70 mg/dL or 100 mg/dL depending on cardiovascular risk category) Evidence of maximally tolerated statin therapy or documented statin intolerance Prescribing clinician is a cardiologist, lipidologist, or relevant specialist (some plans require specialist involvement) Previous trial of other LDL-lowering therapies (PCSK9 inhibitors or ezetimibe, plan-specific) Maintaining thorough PA documentation in secure patient records is essential for both initial approvals and denial appeals
Illegal products containing selective androgen receptor modulators purchased online from Italy: health risks for consumers
EJ Emily Johnson I opted for glutathione injections to help with my skin health and detoxification
During this phase, focus on: Picking a consistent injection day each week Monitoring appetite changes and GI symptoms Staying well-hydrated and eating smaller, more frequent meals if nausea occurs Keeping a brief symptom log to share with your physician Common experiences during this phase include reduced appetite (which is the intended effect), mild nausea, occasional bloating, and changes in bowel habits
Dipeptidyl peptidase-4 (DPP-4) inhibitors in the management of diabetes
